Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Sebastian, Martin [VerfasserIn]   i
 Thomas, Michael [VerfasserIn]   i
Titel:A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer
Verf.angabe:Martin Sebastian, Andreas Schröder, Birgit Scheel, Henoch S. Hong, Anke Muth, Lotta von Boehmer, Alfred Zippelius, Frank Mayer, Martin Reck, Djordje Atanackovic, Michael Thomas, Folker Schneller, Jan Stöhlmacher, Helga Bernhard, Andreas Gröschel, Thomas Lander, Jochen Probst, Tanja Strack, Volker Wiegand, Ulrike Gnad-Vogt, Karl-Josef Kallen, Ingmar Hoerr, Florian von der Muelbe, Mariola Fotin-Mleczek, Alexander Knuth, Sven D. Koch
E-Jahr:2019
Jahr:15 February 2019
Umfang:14 S.
Fussnoten:Gesehen am 07.10.2019
Titel Quelle:Enthalten in: Cancer immunology immunotherapy
Ort Quelle:Berlin : Springer, 1976
Jahr Quelle:2019
Band/Heft Quelle:68(2019), 5, Seite 799-812
ISSN Quelle:1432-0851
Abstract:CV9201 is an RNActive®-based cancer immunotherapy encoding five non-small cell lung cancer-antigens: New York esophageal squamous cell carcinoma-1, melanoma antigen family C1/C2, survivin, and trophoblast glycoprotein. In a phase I/IIa dose-escalation trial, 46 patients with locally advanced (n = 7) or metastatic (n = 39) NSCLC and at least stable disease after first-line treatment received five intradermal CV9201 injections (400-1600 µg of mRNA). The primary objective of the trial was to assess safety. Secondary objectives included assessment of antibody and ex vivo T cell responses against the five antigens, and changes in immune cell populations. All CV9201 dose levels were well-tolerated and the recommended dose for phase IIa was 1600 µg. Most AEs were mild-to-moderate injection site reactions and flu-like symptoms. Three (7%) patients had grade 3 related AEs. No related grade 4/5 or related serious AEs occurred. In phase IIa, antigen-specific immune responses against ≥ 1 antigen were detected in 63% of evaluable patients after treatment. The frequency of activated IgD+CD38hi B cells increased > twofold in 18/30 (60%) evaluable patients. 9/29 (31%) evaluable patients in phase IIa had stable disease and 20/29 (69%) had progressive disease. Median progression-free and overall survival were 5.0 months (95% CI 1.8-6.3) and 10.8 months (8.1-16.7) from first administration, respectively. Two- and 3-year survival rates were 26.7% and 20.7%, respectively. CV9201 was well-tolerated and immune responses could be detected after treatment supporting further clinical investigation.
DOI:doi:10.1007/s00262-019-02315-x
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1007/s00262-019-02315-x
 DOI: https://doi.org/10.1007/s00262-019-02315-x
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:Active cancer immunotherapy
 Clinical trial
 CV9201
 Immunomonitoring
 mRNA
 Non-small cell lung cancer
K10plus-PPN:1678233129
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68435970   QR-Code
zum Seitenanfang